

MEDICAL POLICY

POLICY TITLE	ORTHOPEDIC APPLICATIONS OF STEM-CELL THERAPY (INCLUDING ALLOGRAFT AND BONE SUBSTITUTE PRODUCTS USED WITH AUTOLOGOUS BONE MARROW)
POLICY NUMBER	MP 2.080

CLINICAL BENEFIT	<input type="checkbox"/> MINIMIZE SAFETY RISK OR CONCERN. <input checked="" type="checkbox"/> MINIMIZE HARMFUL OR INEFFECTIVE INTERVENTIONS. <input type="checkbox"/> ASSURE APPROPRIATE LEVEL OF CARE. <input type="checkbox"/> ASSURE APPROPRIATE DURATION OF SERVICE FOR INTERVENTIONS. <input type="checkbox"/> ASSURE THAT RECOMMENDED MEDICAL PREREQUISITES HAVE BEEN MET. <input type="checkbox"/> ASSURE APPROPRIATE SITE OF TREATMENT OR SERVICE.
Effective Date:	3/1/2024

[POLICY RATIONALE](#)
[DISCLAIMER](#)
[POLICY HISTORY](#)

[PRODUCT VARIATIONS](#)
[DEFINITIONS](#)
[CODING INFORMATION](#)

[DESCRIPTION/BACKGROUND](#)
[BENEFIT VARIATIONS](#)
[REFERENCES](#)

I. POLICY

Mesenchymal stem cell therapy (e.g., AlloStem, Osteocel, Osteocel Plus, Ovation, Regenexx, and Trinity Evolution) is considered **investigational** for all orthopedic applications, including use in repair or regeneration of musculoskeletal tissue. There is insufficient evidence to support a general conclusion concerning the health outcomes or benefits associated with this procedure.

Allograft bone products containing viable stem cells, including but not limited to demineralized bone matrix (DBM) with stem cells, is considered **investigational** for all orthopedic applications. There is insufficient evidence to support a general conclusion concerning the health outcomes or benefits associated with this procedure.

Allograft or synthetic bone graft substitutes that must be combined with autologous blood or bone marrow are considered **investigational** for all orthopedic applications. There is insufficient evidence to support a general conclusion concerning the health outcomes or benefits associated with this procedure.

POLICY GUIDELINES

This policy does not address unprocessed allograft bone.

Cross-references:

MP 2.033 Recombinant and Autologous Platelet-Derived Growth Factors as a Treatment of Wound Healing and Other Non-Orthopedic Conditions

MP 4.039 Orthopedic Applications of Platelet Rich Plasma

II. PRODUCT VARIATIONS

[TOP](#)

This policy is only applicable to certain programs and products administered by Capital Blue Cross and subject to benefit variations as discussed in Section VI. Please see additional information below.

MEDICAL POLICY

POLICY TITLE	ORTHOPEDIC APPLICATIONS OF STEM-CELL THERAPY (INCLUDING ALLOGRAFT AND BONE SUBSTITUTE PRODUCTS USED WITH AUTOLOGOUS BONE MARROW)
POLICY NUMBER	MP 2.080

FEP PPO - Refer to FEP Medical Policy Manual. The FEP Medical Policy manual can be found at: <https://www.fepblue.org/benefit-plans/medical-policies-and-utilization-management-guidelines/medical-policies>.

III. DESCRIPTION/BACKGROUND

[TOP](#)

MESENCHYMAL STEM CELLS

Mesenchymal stem cells (MSCs) are multipotent cells (also called stromal multipotent cells) that can differentiate into various tissues including organs, trabecular bone, tendon, articular cartilage, ligaments, muscle, and fat. MSCs are associated with the blood vessels within bone marrow, synovium, fat, and muscle, where they can be mobilized for endogenous repair as occurs with healing of bone fractures. Tissues, such as muscle, cartilage, tendon, ligaments, and vertebral discs, show limited capacity for endogenous repair because of the limited presence of the triad of tissue functional components: vasculature, nerves, and lymphatics. Orthobiologics is a term introduced to describe interventions using cells and biomaterials to support healing and repair. Cell therapy is the application of MSCs directly to a musculoskeletal site. Tissue engineering techniques use MSCs and/or bioactive molecules such as growth factors and scaffold combinations to improve the efficiency of repair or regeneration of damaged musculoskeletal tissues.

Bone marrow aspirate is considered the most accessible source and, thus, the most common place to isolate MSCs for treatment of musculoskeletal disease. However, harvesting MSCs from bone marrow requires a procedure that may result in donor-site morbidity. In addition, the number of MSCs in bone marrow is low, and the number and differentiation capacity of bone marrow–derived MSCs decreases with age, limiting their efficiency when isolated from older patients.

In vivo, the fate of stem cells is regulated by signals in the local 3-dimensional microenvironment from the extracellular matrix and neighboring cells. It is believed that the success of tissue engineering with MSCs will also require an appropriate 3-dimensional scaffold or matrix, culture conditions for tissue-specific induction, and implantation techniques that provide appropriate biomechanical forces and mechanical stimulation. The ability to induce cell division and differentiation without adverse effects, such as the formation of neoplasms, remains a significant concern. Given that each tissue type requires different culture conditions, induction factors (signaling proteins, cytokines, growth factors), and implantation techniques, each preparation must be individually examined.

REGULATORY STATUS

The U.S. Food and Drug Administration (FDA) regulates human cells and tissues intended for implantation, transplantation, or infusion through the Center for Biologics Evaluation and Research, under Code of Federal Regulation (CFR) Title 21, parts 1270 and 1271. MSCs are included in these regulations.

The regulatory status of the stem cell or stem cell-containing products addressed in this review is summarized below.

MEDICAL POLICY

POLICY TITLE	ORTHOPEDIC APPLICATIONS OF STEM-CELL THERAPY (INCLUDING ALLOGRAFT AND BONE SUBSTITUTE PRODUCTS USED WITH AUTOLOGOUS BONE MARROW)
POLICY NUMBER	MP 2.080

Concentrated autologous MSCs do not require approval by FDA. No products using engineered or expanded MSCs have been approved by FDA for orthopedic applications.

Human cells, tissues, and cellular and tissue-based products (HCT/P) are defined as human cells or tissues that are intended for implantation, transplantation, infusion, or transfer into a human recipient. If an HCT/P does not meet the criteria below and does not qualify for any of the stated exceptions, the HCT/P will be regulated as a drug, device, and/or biological product, and applicable regulations and premarket review will be required.

An HCT/P is regulated solely under section 361 of the PHS Act and 21 CFR Part 1271 if it meets all of the following criteria:

- 1) The HCT/P is minimally manipulated;
- 2) The HCT/P is intended for homologous use only, as reflected by the labeling, advertising, or other indications of the manufacturer's objective intent;
- 3) The manufacture of the HCT/P does not involve the combination of the cells or tissues with another article, except for water, crystalloids, or a sterilizing, preserving, or storage agent, provided that the addition of water, crystalloids, or the sterilizing, preserving, or storage agent does not raise new clinical safety concerns with respect to the HCT/P; and
- 4) Either:
 - i) The HCT/P does not have a systemic effect and is not dependent upon the metabolic activity of living cells for its primary function; or
 - ii) The HCT/P has a systemic effect or is dependent upon the metabolic activity of living cells for its primary function, and: a) Is for autologous use; b) Is for allogeneic use in a first-degree or second-degree blood relative; or c) Is for reproductive use."

The FDA does not consider the use of stem cells for orthopedic procedures to be homologous use.

IV. RATIONALE

[TOP](#)

SUMMARY OF EVIDENCE

For individuals who have cartilage defects, meniscal defects, joint fusion procedures, or osteonecrosis who receive stem cell therapy, the evidence includes small randomized controlled trials (RCTs) and nonrandomized comparative trials. Relevant outcomes are symptoms, morbid events, functional outcomes, quality of life, and treatment-related morbidity. Use of mesenchymal stem cells (MSCs) for orthopedic conditions is an active area of research. Despite continued research into the methods of harvesting and delivering treatment, there are uncertainties regarding the optimal source of cells and the delivery method. Studies have included MSCs from bone marrow, adipose tissue, and peripheral blood. Overall, the quality of evidence is low and there is a possibility of publication bias. The strongest evidence to date is

MEDICAL POLICY

POLICY TITLE	ORTHOPEDIC APPLICATIONS OF STEM-CELL THERAPY (INCLUDING ALLOGRAFT AND BONE SUBSTITUTE PRODUCTS USED WITH AUTOLOGOUS BONE MARROW)
POLICY NUMBER	MP 2.080

on MSCs expanded from bone marrow, which includes several phase 1/2 randomized controlled trials. Limitations in these initial trials preclude reaching conclusions, but the results to date do support future study in phase 3 trials. Alternative methods of obtaining MSCs have been reported in a smaller number of trials and with mixed results. Additional study in a larger sample of patients with longer follow-up would be needed to evaluate the long-term efficacy and safety of these procedures. Also, expanded MSCs for orthopedic applications are not FDA approved (concentrated autologous MSCs do not require agency approval). Overall, there is a lack of evidence that clinical outcomes are improved. The evidence is insufficient to determine the effects of the technology on health outcomes.

V. DEFINITIONS

[TOP](#)

Allograft - a tissue graft from a donor of the same species as the recipient but not genetically identical.

Autologous - originating within an individual, i.e., self-donation.

Mesenchymal Stem Cells (MSC) – adult stem cells that are multipotent and can differentiate into several different specialized cell types.

VI. BENEFIT VARIATIONS

[TOP](#)

The existence of this medical policy does not mean that this service is a covered benefit under the member's health benefit plan. Benefit determinations should be based in all cases on the applicable health benefit plan language. Medical policies do not constitute a description of benefits. A member's health benefit plan governs which services are covered, which are excluded, which are subject to benefit limits and which require preauthorization. There are different benefit plan designs in each product administered by Capital Blue Cross. Members and providers should consult the member's health benefit plan for information or contact Capital Blue Cross for benefit information.

VII. DISCLAIMER

[TOP](#)

Capital Blue Cross's medical policies are developed to assist in administering a member's benefits, do not constitute medical advice, and are subject to change. Treating providers are solely responsible for medical advice and treatment of members. Members should discuss any medical policy related to their coverage or condition with their provider and consult their benefit information to determine if the service is covered. If there is a discrepancy between this medical policy and a member's benefit information, the benefit information will govern. If a provider or a member has a question concerning the application of this medical policy to a specific member's plan of benefits, please contact Capital Blue Cross' Provider Services or Member Services. Capital Blue Cross considers the information contained in this medical policy to be proprietary and it may only be disseminated as permitted by law.

VIII. CODING INFORMATION

[TOP](#)

Note: This list of codes may not be all-inclusive, and codes are subject to change at any time. The identification of a code in this section does not denote coverage as coverage is

MEDICAL POLICY

POLICY TITLE	ORTHOPEDIC APPLICATIONS OF STEM-CELL THERAPY (INCLUDING ALLOGRAFT AND BONE SUBSTITUTE PRODUCTS USED WITH AUTOLOGOUS BONE MARROW)
POLICY NUMBER	MP 2.080

determined by the terms of member benefit information. In addition, not all covered services are eligible for separate reimbursement.

Investigational; therefore, not covered:

Procedure Codes								
0263T	0264T	0265T	0489T	0490T	0565T	0566T	20999*	

*Use for aspiration of bone marrow for the purpose of bone grafting, other than spine surgery and other therapeutic musculoskeletal applications

IX. REFERENCES

[TOP](#)

1. Goldberg A, Mitchell K, Soans J, et al. The use of mesenchymal stem cells for cartilage repair and regeneration: a systematic review. *J Orthop Surg Res.* Mar 09 2017; 12(1): 39. PMID 28279182
2. U.S. Food & Drug Administration. *Regulatory Considerations for Human Cells, Tissues, and Cellular and Tissue-Based Products: Minimal Manipulation and Homologous Use*
3. Borakati A, Mafi R, Mafi P, et al. A Systematic Review And Meta-Analysis of Clinical Trials of Mesenchymal Stem Cell Therapy for Cartilage Repair. *Curr Stem Cell Res Ther.* Feb 23 2018; 13(3): 215-225. PMID 28914207
4. Maheshwer B, Polce EM, Paul K, et al. Regenerative Potential of Mesenchymal Stem Cells for the Treatment of Knee Osteoarthritis and Chondral Defects: A Systematic Review and Meta-analysis. *Arthroscopy.* Jan 2021; 37(1): 362-378. PMID 32497658
5. Wiggers TG, Winters M, Van den Boom NA, et al. Autologous stem cell therapy in knee osteoarthritis: a systematic review of randomised controlled trials. *Br J Sports Med.* Oct 2021; 55(20): 1161-1169. PMID 34039582
6. Kim SH, Djaja YP, Park YB, et al. Intra-articular Injection of Culture-Expanded Mesenchymal Stem Cells Without Adjuvant Surgery in Knee Osteoarthritis: A Systematic Review and Meta-analysis. *Am J Sports Med.* Sep 2020; 48(11): 2839-2849. PMID 31874044
7. Jin L, Yang G, Men X, et al. Intra-articular Injection of Mesenchymal Stem Cells After High Tibial Osteotomy: A Systematic Review and Meta-analysis. *Orthop J Sports Med.* Nov 2022; 10(11): 23259671221133784. PMID 36452339
8. Wakitani S, Imoto K, Yamamoto T, et al. Human autologous culture expanded bone marrow mesenchymal cell transplantation for repair of cartilage defects in osteoarthritic knees. *Osteoarthritis Cartilage.* Mar 2002; 10(3): 199-206. PMID 11869080
9. Wakitani S, Nawata M, Tensho K, et al. Repair of articular cartilage defects in the patello-femoral joint with autologous bone marrow mesenchymal cell transplantation: three case reports involving nine defects in five knees. *J Tissue Eng Regen Med.* Jan-Feb 2007; 1(1): 74-9. PMID 18038395
10. Wakitani S, Okabe T, Horibe S, et al. Safety of autologous bone marrow-derived mesenchymal stem cell transplantation for cartilage repair in 41 patients with 45 joints followed for up to 11 years and 5 months. *J Tissue Eng Regen Med.* Feb 2011; 5(2): 146-50. PMID 20603892

MEDICAL POLICY

POLICY TITLE	ORTHOPEDIC APPLICATIONS OF STEM-CELL THERAPY (INCLUDING ALLOGRAFT AND BONE SUBSTITUTE PRODUCTS USED WITH AUTOLOGOUS BONE MARROW)
POLICY NUMBER	MP 2.080

11. Centeno CJ, Schultz JR, Cheever M, et al. Safety and complications reporting on the re-implantation of culture-expanded mesenchymal stem cells using autologous platelet lysate technique. *Curr Stem Cell Res Ther.* Mar 2010; 5(1): 81-93. PMID 19951252
12. Wong KL, Lee KB, Tai BC, et al. Injectable cultured bone marrow-derived mesenchymal stem cells in varus knees with cartilage defects undergoing high tibial osteotomy: a prospective, randomized controlled clinical trial with 2 years' follow-up. *Arthroscopy.* Dec 2013; 29(12): 2020-8. PMID 24286801
13. Emadedin M, Labibzadeh N, Liastani MG, et al. Intra-articular implantation of autologous bone marrow-derived mesenchymal stromal cells to treat knee osteoarthritis: a randomized, triple-blind, placebo-controlled phase 1/2 clinical trial. *Cytotherapy.* Oct 2018; 20(10): 1238-1246. PMID 30318332
14. Lamo-Espinosa JM, Mora G, Blanco JF, et al. Intra-articular injection of two different doses of autologous bone marrow mesenchymal stem cells versus hyaluronic acid in the treatment of knee osteoarthritis: long-term follow up of a multicenter randomized controlled clinical trial (phase I/II). *J Transl Med.* Jul 31 2018; 16(1): 213. PMID 30064455
15. Lamo-Espinosa JM, Mora G, Blanco JF, et al. Intra-articular injection of two different doses of autologous bone marrow mesenchymal stem cells versus hyaluronic acid in the treatment of knee osteoarthritis: multicenter randomized controlled clinical trial (phase I/II). *J Transl Med.* Aug 26 2016; 14(1): 246. PMID 27565858
16. Vega A, Martin-Ferrero MA, Del Canto F, et al. Treatment of Knee Osteoarthritis With Allogeneic Bone Marrow Mesenchymal Stem Cells: A Randomized Controlled Trial. *Transplantation.* Aug 2015; 99(8): 1681-90. PMID 25822648
17. Shapiro SA, Kazmerchak SE, Heckman MG, et al. A Prospective, Single-Blind, Placebo-Controlled Trial of Bone Marrow Aspirate Concentrate for Knee Osteoarthritis. *Am J Sports Med.* Jan 2017; 45(1): 82-90. PMID 27566242
18. Koh YG, Kwon OR, Kim YS, et al. Comparative outcomes of open-wedge high tibial osteotomy with platelet-rich plasma alone or in combination with mesenchymal stem cell treatment: a prospective study. *Arthroscopy.* Nov 2014; 30(11): 1453-60. PMID 25108907
19. Zaffagnini S, Andriolo L, Boffa A, et al. Microfragmented Adipose Tissue Versus Platelet-Rich Plasma for the Treatment of Knee Osteoarthritis: A Prospective Randomized Controlled Trial at 2-Year Follow-up. *Am J Sports Med.* Sep 2022; 50(11): 2881-2892. PMID 35984721
20. Lim HC, Park YB, Ha CW, et al. Allogeneic Umbilical Cord Blood-Derived Mesenchymal Stem Cell Implantation Versus Microfracture for Large, Full-Thickness Cartilage Defects in Older Patients: A Multicenter Randomized Clinical Trial and Extended 5-Year Clinical Follow-up. *Orthop J Sports Med.* Jan 2021; 9(1): 2325967120973052. PMID 33490296
21. Whitehouse MR, Howells NR, Parry MC, et al. Repair of Torn Avascular Meniscal Cartilage Using Undifferentiated Autologous Mesenchymal Stem Cells: From In Vitro Optimization to a First-in-Human Study. *Stem Cells Transl Med.* Apr 2017; 6(4): 1237-1248. PMID 28186682
22. Vangsness CT, Farr J, Boyd J, et al. Adult human mesenchymal stem cells delivered via intra-articular injection to the knee following partial medial meniscectomy: a randomized,

MEDICAL POLICY

POLICY TITLE	ORTHOPEDIC APPLICATIONS OF STEM-CELL THERAPY (INCLUDING ALLOGRAFT AND BONE SUBSTITUTE PRODUCTS USED WITH AUTOLOGOUS BONE MARROW)
POLICY NUMBER	MP 2.080

double-blind, controlled study. J Bone Joint Surg Am. Jan 15 2014; 96(2): 90-8. PMID 24430407

23. *Vanichkachorn J, Peppers T, Bullard D, et al. A prospective clinical and radiographic 12-month outcome study of patients undergoing single-level anterior cervical discectomy and fusion for symptomatic cervical degenerative disc disease utilizing a novel viable allogeneic, cancellous, bone matrix (trinity evolution) with a comparison to historical controls. Eur Spine J. Jul 2016; 25(7): 2233-8. PMID 26849141*
24. *Peppers TA, Bullard DE, Vanichkachorn JS, et al. Prospective clinical and radiographic evaluation of an allogeneic bone matrix containing stem cells (Trinity Evolution(R) Viable Cellular Bone Matrix) in patients undergoing two-level anterior cervical discectomy and fusion. J Orthop Surg Res. Apr 26 2017; 12(1): 67. PMID 28446192*
25. *Jones CP, Loveland J, Atkinson BL, et al. Prospective, Multicenter Evaluation of Allogeneic Bone Matrix Containing Viable Osteogenic Cells in Foot and/or Ankle Arthrodesis. Foot Ankle Int. Oct 2015; 36(10): 1129-37. PMID 25976919*
26. *Eastlack RK, Garfin SR, Brown CR, et al. Osteocel Plus cellular allograft in anterior cervical discectomy and fusion: evaluation of clinical and radiographic outcomes from a prospective multicenter study. Spine (Phila Pa 1976). Oct 15 2014; 39(22): E1331-7. PMID 25188591*
27. *Sen RK, Tripathy SK, Aggarwal S, et al. Early results of core decompression and autologous bone marrow mononuclear cells instillation in femoral head osteonecrosis: a randomized control study. J Arthroplasty. May 2012; 27(5): 679-86. PMID 22000577*
28. *Zhao D, Cui D, Wang B, et al. Treatment of early stage osteonecrosis of the femoral head with autologous implantation of bone marrow-derived and cultured mesenchymal stem cells. Bone. Jan 2012; 50(1): 325-30. PMID 22094904*
29. *American Academy of Orthopaedic Surgeons. Management of Glenohumeral Joint Osteoarthritis Evidence-Based Clinical Practice Guideline*
30. *Kaiser MG, Groff MW, Watters WC, et al. Guideline update for the performance of fusion procedures for degenerative disease of the lumbar spine. Part 16: bone graft extenders and substitutes as an adjunct for lumbar fusion. J Neurosurg Spine. Jul 2014; 21(1): 106-32. PMID 24980593*
31. *Kolasinski SL, Neogi T, Hochberg MC, et al. 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Management of Osteoarthritis of the Hand, Hip, and Knee. Arthritis Care Res (Hoboken). Feb 2020; 72(2): 149-162. PMID 31908149*
32. *Blue Cross Blue Shield Association Medical Policy Reference Manual. 8.01.52, Orthopedic Applications of Stem Cell Therapy (Including Allografts and Bone Substitutes Used With Autologous Bone Marrow). February 2023*

X. POLICY HISTORY

[TOP](#)

MP 2.080	9/15/20 Consensus review. No change to policy statements. Updated references and Summary of Evidence section. Added codes 0565T, 0566T and 20999.
	8/19/21 Consensus review. Updated FEP, regulatory status, definition, and references. To align with BCBSA, deleted codes 20931-20934, 38205-38206,

MEDICAL POLICY

POLICY TITLE	ORTHOPEDIC APPLICATIONS OF STEM-CELL THERAPY (INCLUDING ALLOGRAFT AND BONE SUBSTITUTE PRODUCTS USED WITH AUTOLOGOUS BONE MARROW)
POLICY NUMBER	MP 2.080

38232, 38240-38241, and added codes 0489T-0490T.
3/7/22 Consensus review. No changes to policy statements. References updated.
2/14/2023 Retirement review.
8/30/2023 Minor review. Determined retirement is not best course at this time. Added examples of MSC therapy.
1/19/2024 Administrative update. Clinical benefit added.

[Top](#)

Health care benefit programs issued or administered by Capital Blue Cross and/or its subsidiaries, Capital Advantage Insurance Company®, Capital Advantage Assurance Company®, and Keystone Health Plan® Central. Independent licensees of the Blue Cross BlueShield Association. Communications issued by Capital Blue Cross in its capacity as administrator of programs and provider relations for all companies.